Literature DB >> 7759950

Soluble and membrane-anchored forms of the human IFN-alpha/beta receptor.

D Novick1, B Cohen, N Tal, M Rubinstein.   

Abstract

The recently cloned ligand binding component of the type I human interferon-alpha/beta receptor (IFN-alpha/beta R) and its soluble analogue (p40) were characterized. p40 is a potent inhibitor of type I IFNs and antibodies directed against p40 completely block the activity of type I IFNs in human cells. These antibodies immunoprecipitate cellular 102-kDa (major) and 51-kDa (minor) forms of IFN-alpha/beta R. We find that the 51-kDa IFN-alpha/beta R. Two types of cDNA clones were isolated and sequenced, a 1.5-kb cDNA coding for the transmembrane 51-kDa IFN-alpha/beta R and a 4.5-kb cDNA coding for p40. In addition to ligand binding, IFN-alpha/beta R is directly involved in signaling, because it becomes phosphorylated at Tyr residues on ligand binding and it is physically associated with the cytoplasmic tyrosine kinase JAK1.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7759950     DOI: 10.1002/jlb.57.5.712

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  7 in total

Review 1.  Platelet-derived chemokines: pathophysiology and therapeutic aspects.

Authors:  Hans-Dieter Flad; Ernst Brandt
Journal:  Cell Mol Life Sci       Date:  2010-03-07       Impact factor: 9.261

2.  A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist.

Authors:  W Xu; S R Presnell; J Parrish-Novak; W Kindsvogel; S Jaspers; Z Chen; S R Dillon; Z Gao; T Gilbert; K Madden; S Schlutsmeyer; L Yao; T E Whitmore; Y Chandrasekher; F J Grant; M Maurer; L Jelinek; H Storey; T Brender; A Hammond; S Topouzis; C H Clegg; D C Foster
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-31       Impact factor: 11.205

3.  Peripheral type I interferon receptor correlated with oxidative stress in chronic hepatitis B virus infection.

Authors:  Jing Zhao; Yu-Chen Fan; Feng-Kai Sun; Ze-Hua Zhao; Li-Yuan Wang; Lei-Hua Hu; Yan-Ping Yin; Tao Li; Shuai Gao; Kai Wang
Journal:  J Interferon Cytokine Res       Date:  2013-05-10       Impact factor: 2.607

4.  Different effects of rat interferon alpha, beta and gamma on rat hepatic stellate cell proliferation and activation.

Authors:  Hong Shen; Manna Zhang; Gerald Y Minuk; Yuewen Gong
Journal:  BMC Cell Biol       Date:  2002-04-08       Impact factor: 4.241

5.  Soluble Receptor Isoform of IFN-Beta (sIFNAR2) in Multiple Sclerosis Patients and Their Association With the Clinical Response to IFN-Beta Treatment.

Authors:  Pablo Aliaga-Gaspar; Isaac Hurtado-Guerrero; Nicolas Lundahl Ciano-Petersen; Patricia Urbaneja; Isabel Brichette-Mieg; Virginia Reyes; Jose Luis Rodriguez-Bada; Roberto Alvarez-Lafuente; Rafael Arroyo; Ester Quintana; Lluis Ramió-Torrentà; Ana Alonso; Laura Leyva; Oscar Fernández; Begoña Oliver-Martos
Journal:  Front Immunol       Date:  2021-12-16       Impact factor: 7.561

6.  IFNAR2 relevance in the clinical outcome of individuals with severe COVID-19.

Authors:  Ingrid Fricke-Galindo; Alfonso Martínez-Morales; Leslie Chávez-Galán; Ranferi Ocaña-Guzmán; Ivette Buendía-Roldán; Gloria Pérez-Rubio; Rafael de Jesus Hernández-Zenteno; Abigail Verónica-Aguilar; Aimé Alarcón-Dionet; Hiram Aguilar-Duran; Ilse Adriana Gutiérrez-Pérez; Oscar Zaragoza-García; Jesús Alanis-Ponce; Angel Camarena; Brandon Bautista-Becerril; Karol J Nava-Quiroz; Mayra Mejía; Iris Paola Guzmán-Guzmán; Ramcés Falfán-Valencia
Journal:  Front Immunol       Date:  2022-07-29       Impact factor: 8.786

7.  Antiviral, Immunomodulatory and Antiproliferative Activities of Recombinant Soluble IFNAR2 without IFN-ß Mediation.

Authors:  Isaac Hurtado-Guerrero; Bruno Hernáez; María J Pinto-Medel; Esther Calonge; José L Rodriguez-Bada; Patricia Urbaneja; Ana Alonso; Natalia Mena-Vázquez; Pablo Aliaga; Shohreh Issazadeh-Navikas; José Pavia; Laura Leyva; José Alcamí; Antonio Alcamí; Óscar Fernández; Begoña Oliver-Martos
Journal:  J Clin Med       Date:  2020-03-31       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.